A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer

Real-world Treatment Patterns and Effectiveness Among Patients With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07386847

Enrollment

Registered

2026-02-04

Start date

2026-02-12

Completion date

2026-03-30

Last updated

2026-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced or Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma

Keywords

Metastatic Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma

Brief summary

Bladder cancer (urothelial carcinoma) is a disease where cells in the bladder grow out of control. The bladder is an organ in the lower part of the body that stores urine. When someone has bladder cancer, abnormal cells form in the bladder and can spread to other parts of the body if not treated. Bladder cancer that has spread outside the bladder is called advanced or metastatic bladder cancer. The purpose of this study is to examine how long it takes for adults with advanced or metastatic bladder cancer to experience worsening of their disease following their first treatment . The researchers will also describe which medicines these patients use as their first treatment for the disease. This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information from cancer clinics (Flatiron Health electronic health records). The study will include patients' information from the database who: * Were identified to have advanced or metastatic bladder cancer. * Started their first treatment after 01 Apr 2023. * Were 18 years of age or older when they were diagnosed with advanced disease.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults (18 years or older) diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC) in the Flatiron Health database. * Started first line systemic treatment for la/mUC during the study period. * Received care in the United States, as the study is U.S.-based. * Has sufficient available real-world data to assess treatment patterns and outcomes (e.g., treatment dates, follow-up, response/survival information).

Exclusion criteria

* Histology other than transitional cell (urothelial) carcinoma. * Primary site of disease other than bladder, renal pelvis, ureter, or urethra * Clinical trial participation.

Design outcomes

Primary

Measure	Time frame	Description
Real world Progression Free Survival (rwPFS)	Up to 2 Years	Time from initiation of first line treatment for la/mUC to the earliest of disease progression or death, based on real-world data sources.

Secondary

Measure	Time frame	Description
Real world Overall Tumor Response (rwOTR)	Up to 2 Years	Proportion of patients achieving tumor response (e.g., complete or partial response) based on real-world oncology data.

Countries

United States

Contacts

STUDY_DIRECTORPfizer CT.gov Call Center

Pfizer

Outcome results